133 related articles for article (PubMed ID: 31157509)
21. Functional analysis of clinical
Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
[TBL] [Abstract][Full Text] [Related]
22. BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Sabatier R; Adélaïde J; Finetti P; Ferrari A; Huiart L; Sobol H; Chaffanet M; Birnbaum D; Bertucci F
Genes Chromosomes Cancer; 2010 Dec; 49(12):1143-51. PubMed ID: 20842729
[TBL] [Abstract][Full Text] [Related]
23. [Cooperation between a somatic mutation and a genetic susceptibility variant in Ewing sarcoma].
Grünewald TG; Gilardi-Hebenstreit P; Charnay P; Delattre O
Med Sci (Paris); 2016 Apr; 32(4):323-6. PubMed ID: 27137684
[No Abstract] [Full Text] [Related]
24. Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study.
DuBois SG; Goldsby R; Segal M; Woo J; Copren K; Kane JP; Pullinger CR; Matthay KK; Witte J; Lessnick SL; Robison LL; Bhatia S; Strong LC
Pediatr Blood Cancer; 2012 Jul; 59(1):52-6. PubMed ID: 21793187
[TBL] [Abstract][Full Text] [Related]
25. Genetically Engineered Mouse Model in Ewing Sarcoma.
Tanaka M; Nakamura T
Methods Mol Biol; 2021; 2226():183-189. PubMed ID: 33326102
[TBL] [Abstract][Full Text] [Related]
26. Osteosarcoma without prior retinoblastoma related to RB1 low-penetrance germline pathogenic variants: A novel type of RB1-related hereditary predisposition syndrome?
Imbert-Bouteille M; Gauthier-Villars M; Leroux D; Meunier I; Aerts I; Lumbroso-Le Rouic L; Lejeune S; Delnatte C; Abadie C; Pujol P; Houdayer C; Corsini C
Mol Genet Genomic Med; 2019 Dec; 7(12):e913. PubMed ID: 31568710
[TBL] [Abstract][Full Text] [Related]
27. The genomic landscape of pediatric Ewing sarcoma.
Crompton BD; Stewart C; Taylor-Weiner A; Alexe G; Kurek KC; Calicchio ML; Kiezun A; Carter SL; Shukla SA; Mehta SS; Thorner AR; de Torres C; Lavarino C; Suñol M; McKenna A; Sivachenko A; Cibulskis K; Lawrence MS; Stojanov P; Rosenberg M; Ambrogio L; Auclair D; Seepo S; Blumenstiel B; DeFelice M; Imaz-Rosshandler I; Schwarz-Cruz Y Celis A; Rivera MN; Rodriguez-Galindo C; Fleming MD; Golub TR; Getz G; Mora J; Stegmaier K
Cancer Discov; 2014 Nov; 4(11):1326-41. PubMed ID: 25186949
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1.
Huertas-Martínez J; Court F; Rello-Varona S; Herrero-Martín D; Almacellas-Rabaiget O; Sáinz-Jaspeado M; Garcia-Monclús S; Lagares-Tena L; Buj R; Hontecillas-Prieto L; Sastre A; Azorin D; Sanjuan X; López-Alemany R; Moran S; Roma J; Gallego S; Mora J; García Del Muro X; Giangrande PH; Peinado MA; Alonso J; de Alava E; Monk D; Esteller M; Tirado OM
Cancer Lett; 2017 Feb; 386():196-207. PubMed ID: 27894957
[TBL] [Abstract][Full Text] [Related]
29. Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.
Spurdle AB; Marquart L; McGuffog L; Healey S; Sinilnikova O; Wan F; Chen X; Beesley J; Singer CF; Dressler AC; Gschwantler-Kaulich D; Blum JL; Tung N; Weitzel J; Lynch H; Garber J; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Conroy D; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Selkirk CG; Daly M; Isaacs C; Stoppa-Lyonnet D; Sinilnikova OM; Buecher B; Belotti M; Mazoyer S; Barjhoux L; Verny-Pierre C; Lasset C; Dreyfus H; Pujol P; Collonge-Rame MA; ; Rookus MA; Verhoef S; Kriege M; Hoogerbrugge N; Ausems MG; van Os TA; Wijnen J; Devilee P; Meijers-Heijboer HE; Blok MJ; Heikkinen T; Nevanlinna H; Jakubowska A; Lubinski J; Huzarski T; Byrski T; Durocher F; Couch FJ; Lindor NM; Wang X; Thomassen M; Domchek S; Nathanson K; Caligo M; Jernström H; Liljegren A; Ehrencrona H; Karlsson P; ; Ganz PA; Olopade OI; Tomlinson G; Neuhausen S; Antoniou AC; Chenevix-Trench G; Rebbeck TR
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1032-8. PubMed ID: 21393566
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
Haanpää M; Pylkäs K; Moilanen JS; Winqvist R
BMC Med Genet; 2013 Aug; 14():82. PubMed ID: 23941127
[TBL] [Abstract][Full Text] [Related]
31. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
[TBL] [Abstract][Full Text] [Related]
32. Ewing Sarcoma, an Update on Molecular Pathology with Therapeutic Implications.
de Alava E
Surg Pathol Clin; 2017 Sep; 10(3):575-585. PubMed ID: 28797503
[TBL] [Abstract][Full Text] [Related]
33. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
34. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.
Karppinen SM; Heikkinen K; Rapakko K; Winqvist R
J Med Genet; 2004 Sep; 41(9):e114. PubMed ID: 15342711
[No Abstract] [Full Text] [Related]
35. RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.
Gharanei S; Brini AT; Vaiyapuri S; Alholle A; Dallol A; Arrigoni E; Kishida T; Hiruma T; Avigad S; Grimer R; Maher ER; Latif F
Epigenetics; 2013 Sep; 8(9):893-8. PubMed ID: 23887284
[TBL] [Abstract][Full Text] [Related]
36. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
[TBL] [Abstract][Full Text] [Related]
37. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
38. The potential of KDM3A as a therapeutic target in Ewing Sarcoma and other cancers.
Jedlicka P
Expert Opin Ther Targets; 2017 Nov; 21(11):997-999. PubMed ID: 29022407
[No Abstract] [Full Text] [Related]
39. [Functional genomics of Ewing sarcoma].
Grünewald TGP
Pathologe; 2017 Nov; 38(Suppl 2):198-201. PubMed ID: 28849372
[TBL] [Abstract][Full Text] [Related]
40. Chromosomal analysis in Ewing sarcoma.
Callen DF; Smith RD; Bourne AJ
Pathology; 1987 Jan; 19(1):64-6. PubMed ID: 3588029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
